SNY.TO Sanofi CDR (CAD Hedged)
- Market cap
- -
- P/E
- 24.0x
- P/B
- 0.23x
- ROE
- 9.1%
- Dividend yield
- 4.03%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SNY.TO undervalued?
Graham numberThe Graham number of Sanofi CDR (CAD Hedged) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sanofi CDR (CAD Hedged) fundamental analysis
No fundamental analysis for Sanofi CDR (CAD Hedged) yet.
Sanofi CDR (CAD Hedged) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sanofi CDR (CAD Hedged)
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, boo…
Full company profileSanofi CDR (CAD Hedged) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sanofi CDR (CAD Hedged) annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 45.4B | 41.6B | 44.3B | 46.7B | 51.7B |
| Gross Profit | 31.7B | 29.0B | 31.1B | 33.7B | 38.7B |
| Operating Income | 10.7B | 6.96B | 7.25B | 6.34B | 12.5B |
| EBITDA | 13.5B | 11.3B | 11.0B | 12.5B | 12.5B |
| Net Income | 8.37B | 5.40B | 5.56B | 7.81B | 6.64B |
| EPS | 6.68 | 4.32 | 4.44 | 6.47 | 5.54 |
| Balance Sheet | |||||
| Total Assets | 127B | 126B | 133B | 127B | 130B |
| Total Liabilities | 51.9B | 52.4B | 55.3B | 55.4B | 57.0B |
| Shareholders' Equity | 74.8B | 74.0B | 77.5B | 71.4B | 72.9B |
| Cash & Short-term Investments | 13.4B | 8.98B | 7.93B | 8.47B | 5.97B |
| Cash Flow | |||||
| Operating Cash Flow | 10.5B | 10.3B | 8.91B | 10.9B | 11.4B |
| Capital Expenditure | 2.20B | 2.91B | 3.20B | 3.54B | 0.00 |
| Free Cash Flow | 8.42B | 7.35B | 5.89B | 7.21B | 11.4B |
| Ratios | |||||
| ROE | 11.2% | 7.3% | 7.2% | 10.9% | 9.1% |
| ROA | 6.6% | 4.3% | 4.2% | 6.2% | 5.1% |
| Net Profit Margin | 18.4% | 13.0% | 12.6% | 16.7% | 12.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Sanofi CDR (CAD Hedged) dividends
- Dividend yield
- 4.03%
- Forward dividend
- -
- Payout ratio
- 61.1%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 4.77B | 3.95 | 61.1% |
| 2024 | EUR 4.70B | 3.75 | 84.6% |
| 2023 | EUR 4.45B | 3.56 | 82.5% |
| 2022 | EUR 4.17B | 3.33 | 49.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Sanofi CDR (CAD Hedged)
Ownership data of Sanofi CDR (CAD Hedged) is not available yet.
Sanofi CDR (CAD Hedged) company profile
- Company name
- Sanofi CDR (CAD Hedged)
- Ticker
- SNY.TO
- Exchange
- Toronto Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 82,878
- Fiscal year end
- December
- Address
- Website
- -
About Sanofi CDR (CAD Hedged)
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as a strategic alliance with the Department of Health " Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.